MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/20406223221077958

Медицинская библиотека · Therapeutic advances in chronic disease · 2022

Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

El-Kady Rasha R, Ali Amani K, El Wakeel Lamia M, Sabri Nagwa A, Shawki May A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Nicotinamide has been reported to protect against liver steatosis and metabolic imbalances in nonalcoholic fatty liver disease (NAFLD) in animal models.

OBJECTIVES

The objective was to investigate the efficacy and safety of nicotinamide supplementation in diabetic NAFLD patients.

DESIGN

This is a prospective randomized controlled open label study.

METHODS

Seventy diabetic NAFLD patients were randomly assigned either to the nicotinamide group (n = 35) who received nicotinamide 1000 mg once daily for 12 weeks in addition to their antidiabetic therapy or the control group (n = 35) who received their antidiabetic therapy only. The primary outcome was improvement in steatosis score, while secondary outcomes included assessment of liver stiffness, liver enzymes, lipid profile, insulin resistance, serum malondialdehyde, serum adiponectin, and patients' quality of life (QOL).

RESULTS

Only 61 patients completed the study; 31 in the nicotinamide group and 30 in the control group. Comparisons between groups and within groups revealed nonsignificant changes in steatosis and fibrosis scores. However, significant reduction was observed in liver enzymes with a median decrease in alanine transaminase of 26.6% versus 0.74% in nicotinamide and control groups, respectively. After 12 weeks of treatment, the nicotinamide group showed significantly lower levels of low-density lipoprotein cholesterol (p value = 0.004), total cholesterol (p value = 0.006), and insulin resistance marker (p value = 0.005) compared with control. Serum triglycerides, malondialdehyde, and adiponectin levels were all comparable between the two groups. Regarding QOL, a significant improvement was detected in the total scores and the activity and fatigue domains scores.

CONCLUSION

Nicotinamide at a dose of 1000 mg daily was tolerable, improved metabolic abnormalities and QOL of diabetic NAFLD patients with no effect on liver fibrosis or steatosis.

TRIAL REGISTRATION: The study was registered at clinicaltrials.gov and given the ID number: 'NCT03850886'. https://clinicaltrials.gov/ct2/show/NCT03850886.

Для цитирования: El-Kady Rasha R, Ali Amani K, El Wakeel Lamia M, Sabri Nagwa A, Shawki May A. Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.. Therapeutic advances in chronic disease. 2022. DOI: 10.1177/20406223221077958.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.